MedWatch

Analyst: Zealand Pharma should benefit from Amylin sale

A price of DKK 40 billion for the Novo Nordisk rival Amylin Pharmaceuticals shows that the market for GLP-1 drugs is on the rise. But it will primarily be detectable in Zealand Pharma’s share price, believes analyst.

Foto: Zealand Pharma/PR

Bristol Myers Squibb’s recent acquisition of the former Eli Lilly partner Amylin Pharmaceuticals probably won’t have an effect on the share price of Novo Nordisk. Because, even though the deal could have a positive effect on the value of Novo Nordisk’s GLP-1 segment, the Novo share is already valued fairly high.

There is, however, a good chance that the Danish biotech company Zealand Pharma could cash in on the deal, as the French pharmaceutical group Sanofi is no longer in the running to take over Amylin’s GLP-1 products Buetta and Bydureon. That is the assessment of analyst Michael Friis Jørgensen from Alm. Brand Markets.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Her er de vigtigste nyheder fra MedWatch i uge 39

Et konsortium står til at overtage Ferrosan Medical Devices, der kan være klar til en børsnotering inden for en femårig tidshorisont. Derudover fortsætter kampen om medarbejderne i branchen, mens Novo Nordisk har indgået en ny aftale. Gik du glip af noget?

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier